Growth hormone is a chain of 191 amino acids, but the part that burns fat sits in the last fifteen. The rest of the molecule does something else entirely: it drives IGF-1 output, cell growth and changes in glucose handling. Any lipolysis measured with whole hGH gets tangled up with all of that. This article looks at how AOD-9604 isolates the fat-burning stretch of hGH, how it compares with the unmodified Fragment 176-191 and with beta-lipotropin fragments, and what the differences mean for assay design and reagent handling in the lab.
Why isolate the lipolytic domain at all
hGH is a 191-residue polypeptide, and its activity is not spread evenly across that chain. The fat-reducing behaviour sits in the C-terminal region. The anabolic and growth-signalling behaviour needs the intact protein engaging the full-length growth hormone receptor. In the whole hormone those two properties always travel together, which is exactly the problem for anyone running a controlled fat-oxidation experiment.
Whole hGH as a lipolytic stimulus creates three well-known problems:
- Direct triglyceride breakdown cannot easily be separated from downstream IGF-1 signalling.
- The insulin resistance and hyperinsulinaemia that come with whole growth hormone shift the metabolic baseline you are measuring against.
- Proliferative effects change the cell population itself over a multi-day incubation, which quietly changes your denominator.
Isolate the C-terminal fragment and those confounders disappear. What is left is a stimulus that acts on the adipocyte and very little else.
What AOD-9604 is
AOD-9604 is a synthetic analogue of the lipolytic C-terminal domain of human growth hormone, spanning residues 177 to 191, with an engineered tyrosine residue added at the N-terminus. Think of it as the fat-oxidation domain of hGH with a stability fix built in, not as a growth hormone analogue in any meaningful sense.
Two properties make it useful as a reagent:
- Selective lipolysis. It stimulates triglyceride breakdown and inhibits lipogenesis directly in adipocytes, with no measurable effect on protein synthesis.
- Metabolic cleanliness. It has no meaningful binding affinity for the full-length hGH receptor, so it does not trigger IGF-1 production, does not alter glucose homeostasis, and does not reproduce the hyperinsulinaemia and insulin resistance seen with whole growth hormone.
That combination is what makes it a clean tool for analytical work: the lipolytic arm of growth hormone biology, isolated, with a much shorter list of variables to control for.
AOD-9604 versus hGH Fragment 176-191
Both sequences target the same lipolytic domain. They behave differently once they sit in culture media at 37 degrees.
Standard Fragment 176-191 breaks down quickly under enzymatic attack, and its secondary structure unfolds in vitro. Over a long incubation that produces a decaying stimulus: the concentration you applied at hour zero is not the concentration acting on the cells at the end of the run, and replicate-to-replicate variance climbs as a result.
The added tyrosine in AOD-9604 changes that picture. It substantially improves molecular stability and resistance to cellular peptidases, while keeping the fragment's lipolytic activity intact, so the pharmacology of the domain survives and the durability improves. In practice that shows up in two ways:
- Longer effective half-life. The peptide holds its active monomeric shape for longer in incubation media than the unmodified fragment does.
- More consistent lipolysis. Glycerol and free fatty acid release in white adipose tissue models is markedly more reproducible across wells and across runs.
Beta-lipotropin fragments as a comparator
Beta-lipotropin and its specialised fragments are classic endocrinology tools that have returned to favour in fat-oxidation work. Transcribed from the POMC precursor, they bind directly to melanocortin receptors on the adipocyte surface and trigger triglyceride breakdown without any secondary hepatic processing. That makes them a dependable positive control and a good way to set a baseline lipolysis rate before introducing a test compound.
Choosing between the three
| Property | AOD-9604 | hGH Fragment 176-191 | Beta-lipotropin fragments |
|---|---|---|---|
| Origin | hGH C-terminus, residues 177-191 | hGH C-terminus, residues 176-191 | POMC precursor, beta-lipotropin |
| Key structural feature | Engineered N-terminal tyrosine | Unmodified native sequence | Native lipotropin sequence |
| Adipocyte engagement | Lipolytic signalling retained (mechanism under study) | Lipolytic fragment activity | Direct melanocortin receptor binding |
| Full-length hGH receptor | No meaningful affinity | No meaningful affinity | Not applicable |
| Stability in culture media | High, peptidase resistant | Lower, rapid enzymatic cleavage | Sequence dependent |
| Best suited to | Long incubations, kinetic and dose-response work | Short-window comparative studies | Baseline and positive-control lipolysis |
The lipolytic cascade and what you can measure
The available readouts follow directly from the mechanism. Receptor engagement on the adipocyte surface stimulates adenylate cyclase, which raises intracellular cAMP sharply. That cascade phosphorylates hormone-sensitive lipase, which then hydrolyses stored triglyceride and releases free fatty acids and glycerol into the medium.
Each step gives you something to quantify:
- cAMP accumulation, an early, proximal signal of receptor engagement.
- Hormone-sensitive lipase phosphorylation by immunoblot, confirming the cascade rather than assuming it.
- Glycerol release into the medium, the standard stoichiometric proxy for triglyceride hydrolysis.
- Free fatty acid release, useful alongside glycerol because re-esterification can decouple the two.
Because AOD-9604 does not disturb glucose homeostasis or protein synthesis, you can read these results without first correcting for a shifted metabolic baseline. That is the point of using the isolated domain in the first place.
Purity, stability and handling
Modified peptide fragments are fragile, and the kinetic differences above are subtle enough that reagent quality decides whether you can see them at all. A partially degraded lot still produces lipolysis. It just produces it at an unknown effective concentration, which is worse than no signal because it looks like data.
Three points matter in practice:
- Synthesis precision. Truncated or deletion sequences in a lot shift the true molar concentration of active peptide. Every Pepsup lot is verified by independent European HPLC testing.
- Thermal history. Sourcing through Chinese dropshipping typically means weeks of uncontrolled heat exposure in ocean freight. Our in-stock items are held in temperature-controlled European facilities and shipped domestically, so the material arrives with its enzymatic activity intact.
- Laboratory storage. Keep lyophilised material cold and dark, reconstitute right before use, aliquot to avoid repeated freeze-thaw cycles, and treat reconstituted stock as short-lived.
Where it fits in a metabolic research panel
AOD-9604 earns its place when you need the lipolytic arm of growth hormone biology cleanly separated from everything else the hormone does. Run it against a lipotropin fragment as a mechanistic control, or against unmodified Fragment 176-191 when the question is stability rather than potency. It also works as a reference stimulus when characterising other compounds in our metabolic research range, since its effects are narrow enough to make a comparison interpretable.
Full sequence details, batch documentation and current European stock for AOD-9604 and related lipolytic fragments are listed in the Pepsup shop.
All products supplied by Pepsup are for laboratory research use only. Not for human or veterinary consumption, and not for diagnostic or therapeutic use.